Maria Jose Lafuente-Monasterio

Maria Jose Lafuente-Monasterio

Auto-generated profile, based on publicly available information

Maria Jose Lafuente-Monasterio

Tres Cantos Medicines Development Campus-Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid 28760, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in Science
Verified
Journal Article
Closed access
PDF file
MAMahmood M. Alam
Mahmood M. Alam
ASAna Sanchez-Azqueta
Ana Sanchez-Azqueta
OJOmar Janha
Omar Janha
EFErika L. Flannery
Erika L. Flannery
AMAmit Mahindra
Amit Mahindra
ATAndrew B. Tobin
Andrew B. Tobin
Targeting parasite's protein kinase: Malaria elimination goals are constantly eroded by the challenge of emerging drug and insecticide resistance. Alam et al. have taken established drug targets—CLK protein kinases involved in regulation of RNA splicing—and investigated how inhibition of the parasite's enzymes blocks completion of its complex life cycle. They identified an inhibitor of the parasite's CLK protein kinase that was 100-fold less active against the most closely related human protein kinase and effective at clearing rodent malaria parasites. Not only does this compound halt the development of sexual stages but it also limits transmission to the mosquito vector of the parasite, a key requirement for malaria drugs. Science , this issue p. eaau1682

19 October 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
LALauren B. Arendse
Lauren B. Arendse
JMJames M. Murithi
James M. Murithi
TQTarrick Qahash
Tarrick Qahash
Charisse Flerida PasajeCharisse Flerida Pasaje
Charisse Flerida Pasaje
LGLuiz C. Godoy
Luiz C. Godoy
KCKelly Chibale
Kelly Chibale
Compounds acting on multiple targets are critical to combating antimalarial drug resistance. Here, we report that the human “mammalian target of rapamycin” (mTOR) inhibitor sapanisertib has potent prophylactic liver stage activity, in vitro and in vivo asexual blood stage (ABS) activity, and transmission-blocking activity against the protozoan parasite Plasmodium spp. Chemoproteomics studies revealed multiple potential Plasmodium kinase targets, and potent inhibition of Plasmodium phosphatidylinositol 4-kinase type III beta (PI4Kβ) and cyclic guanosine monophosphate–dependent protein kinase (PKG) was confirmed in vitro. Conditional knockdown of PI4Kβ in ABS cultures modulated parasite sensitivity to sapanisertib, and laboratory-generated P. falciparum sapanisertib resistance was mediated by mutations in PI4Kβ. Parasite metabolomic perturbation profiles associated with sapanisertib and other known PI4Kβ and/or PKG inhibitors revealed similarities and differences between chemotypes, potentially caused by sapanisertib targeting multiple parasite kinases. The multistage activity of sapanisertib and its in vivo antimalarial efficacy, coupled with potent inhibition of at least two promising drug targets, provides an opportunity to reposition this pyrazolopyrimidine for malaria.

4 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RMRebecca E. K. Mandt
Rebecca E. K. Mandt
MLMaria Jose Lafuente-Monasterio
Maria Jose Lafuente-Monasterio
TSTomoyo Sakata-Kato
Tomoyo Sakata-Kato
MLMadeline R. Luth
Madeline R. Luth
DSDelfina Segura
Delfina Segura
DWDyann F. Wirth
Dyann F. Wirth
The malaria parasite Plasmodium falciparum readily develops resistance to dihydroorotate dehydrogenase inhibitors in vitro and in a mouse model of infection.

5 August 2014 in Acta Crystallographica Section A Foundations and Advances
Verified
Journal Article
Open access
PRPaul Rowland
Paul Rowland
onkar singhonkar singh
onkar singh
LRLeila Ross
Leila Ross
FGFrancisco Gamo
Francisco Gamo
MLMaria Lafuente-Monasterio
Maria Lafuente-Monasterio
DWDyann Wirth
Dyann Wirth
Malaria is a preventable and treatable disease, yet annually there are still hundreds of thousands of malaria-related deaths. The disease is caused by infection with mosquito-borne Plasmodium parasites. With hundreds of millions of cases each year there is a very high potential for drug resistance and this has compromised many existing therapies. One target under investigation is the enzyme dihydroorotate dehydrogenase (DHODH) which catalyses the rate-limiting step of pyrimidine biosynthesis and is an essential enzyme in the malaria parasite. There are currently several Plasmodium-selective DHODH inhibitors under development. To investigate the potential for drug resistance against DHODH inhibitors in vitro resistance selections were carried out using known inhibitors from different structural classes [1]. These studies identified point mutations in the drug binding site which lead to reduced sensitivity to the inhibitors, and in some cases increased sensitivity to a different inhibitor, suggesting a novel combination therapy approach to combat resistance. To help understand the significance of the inhibitor binding site mutations we determined the crystal structures of P. falciparum DHODH in complex with the inhibitors Genz-669178, IDI-6253 and IDI-6273. Co-crystallisation experiments led to a new crystal form in each case. Here we describe the crystal structures, the binding modes of the inhibitors and the great flexibility of the binding site, which is able to adjust to accommodate different inhibitor series. The structural role of the resistance mutations is also discussed.